News Release ImmunoMet Therapeutics Announces Closing of Series B Expansion Financing February 5, 2020 - Houston, TexasImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to develop novel anti-tumor…
News Release ImmunoMet Therapeutics to Participate at the 2020 BIO CEO & Investor Conference February 5, 2020 - Houston, TexasImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to…
News Release ImmunoMet Therapeutics to Participate in the Biotech Showcase Investor Conference in San Francisco December 4, 2019 - Houston, TexasHOUSTON, TEXAS December 4, 2019 ImmunoMet Therapeutics, a clinical stage biotechnology…
News Release ImmunoMet Therapeutics to Participate at the 2019 BIO Investor Forum and BIO-Europe Conferences October 7, 2019 - Houston, TexasImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to…
Immunomet Presents Safety Data from its Ongoing Phase1 Study at AACR 2019 March, 2019 - Houston, TexasImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel…
ImmunoMet Raises $8.6 million in Convertible Note Financing May, 2018 - Houston, TexasImmunoMet Therapeutics, a private biotechnology company focused on utilizing cellular metabolism to develop novel tumor and cellular metabolism…